Pfizer Inc. (PFE) and Astellas Pharma Announce Survival Results from Phase 3 EMBARK Study

MSN
2025.10.26 11:50
portai
I'm PortAI, I can summarize articles.

Pfizer Inc. (NYSE:PFE) and Astellas Pharma US Inc. announced the final overall survival results from their Phase 3 EMBARK study on October 19. The study evaluated the effectiveness of XTANDI in combination with leuprolide as a monotherapy for men with non-metastatic hormone-sensitive prostate cancer. Pfizer is also noted as one of the most undervalued long-term stocks to buy right now.

Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.